Viewing Study NCT06649292

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 3:31 PM
Ignite Modification Date: 2026-02-02 @ 5:21 PM
Study NCT ID: NCT06649292
Status: RECRUITING
Last Update Posted: 2024-12-12
First Post: 2024-10-17
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma View
Keywords: